Clinical Case Scenarios in the Management of Non-diabetic Chronic Kidney Diseases

Research conducted in India has shown that there is a high prevalence of non-diabetic kidney disease (NDKD) among Indian patients. Sodium-glucose co-transporter 2 inhibitors (SGLT2i) are emerging as potential treatments for preventing the progression of chronic kidney disease to advanced stages, regardless of their anti-diabetic effects. Dapagliflozin, which has been approved by the Central Drugs Standard Control Organization, is the SGLT2i drug class approved for use in both DKD and NDKD patients. Taking this validation into account, the case series was planned to showcase four different real-life case studies in an Indian clinical setting, which involved the utilization of dapagliflozin in different patient profiles with NDKD. The real-world cases substantiate the renoprotective effects of dapagliflozin as seen by changes in the estimated glomerular filtration rate levels and proteinuria post-treatment. These case scenarios highlight the benefits of reducing renal risk factors in patients with NDKD. Notably, in all the cases, the risk of renal disease progression was delayed in NDKD patients with dapagliflozin.